Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Seasonal Allergic Rhinitis Overview 6 Therapeutics Development 7 Pipeline Products for Seasonal Allergic Rhinitis - Overview 7 Seasonal Allergic Rhinitis - Therapeutics under Development by Companies 8 Seasonal Allergic Rhinitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Seasonal Allergic Rhinitis - Products under Development by Companies 11 Seasonal Allergic Rhinitis - Companies Involved in Therapeutics Development 12 Allergy Therapeutics Plc 12 Faes Farma, S.A. 13 Glenmark Pharmaceuticals Ltd. 14 Hisamitsu Pharmaceutical Co., Inc. 15 Merck & Co., Inc. 16 Pfizer Inc. 17 Shionogi & Co., Ltd. 18 VentiRx Pharmaceuticals, Inc. 19 Seasonal Allergic Rhinitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 asapiprant - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 bilastine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 desloratadine - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 emedastine difumarate - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 GSP-301 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 PF-06444752 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 PF-06444753 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Pollinex Quattro Tree - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 VTX-1463 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Seasonal Allergic Rhinitis - Dormant Projects 43 Seasonal Allergic Rhinitis - Discontinued Products 45 Seasonal Allergic Rhinitis - Product Development Milestones 46 Featured News & Press Releases 46 May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis 46 Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN 46 Oct 11, 2013: FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49

List of Tables Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Seasonal Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016 12 Seasonal Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016 13 Seasonal Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 14 Seasonal Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 15 Seasonal Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016 16 Seasonal Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016 17 Seasonal Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016 18 Seasonal Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Seasonal Allergic Rhinitis - Dormant Projects, H2 2016 43 Seasonal Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016 44 Seasonal Allergic Rhinitis - Discontinued Products, H2 2016 45 List of Figures Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Targets, H2 2016 21 Number of Products by Stage and Targets, H2 2016 21 Number of Products by Mechanism of Actions, H2 2016 23 Number of Products by Stage and Mechanism of Actions, H2 2016 23 Number of Products by Routes of Administration, H2 2016 25 Number of Products by Stage and Routes of Administration, H2 2016 25 Number of Products by Molecule Types, H2 2016 27 Number of Products by Stage and Molecule Types, H2 2016 27

Allergy Therapeutics Plc Faes Farma, S.A. Glenmark Pharmaceuticals Ltd. Hisamitsu Pharmaceutical Co., Inc. Merck & Co., Inc. Pfizer Inc. Shionogi & Co., Ltd. VentiRx Pharmaceuticals, Inc.